494 related articles for article (PubMed ID: 18188457)
1. Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells.
Arenas F; Hervias I; Uriz M; Joplin R; Prieto J; Medina JF
J Clin Invest; 2008 Feb; 118(2):695-709. PubMed ID: 18188457
[TBL] [Abstract][Full Text] [Related]
2. Role of the anion exchanger 2 in the pathogenesis and treatment of primary biliary cirrhosis.
Medina JF
Dig Dis; 2011; 29(1):103-12. PubMed ID: 21691115
[TBL] [Abstract][Full Text] [Related]
3. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Chazouillères O; Wendum D; Serfaty L; Rosmorduc O; Poupon R
J Hepatol; 2006 Feb; 44(2):400-6. PubMed ID: 16356577
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of colchicine in patients with primary biliary cirrhosis poorly responsive to ursodiol and methotrexate.
Lee YM; Kaplan MM
Am J Gastroenterol; 2003 Jan; 98(1):205-8. PubMed ID: 12526960
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of early primary biliary cirrhosis: possible insights into the mechanism of action of ursodeoxycholic acid.
Chen L; Borozan I; Milkiewicz P; Sun J; Meng X; Coltescu C; Edwards AM; Ostrowski MA; Guindi M; Heathcote EJ; McGilvray ID
Liver Int; 2008 Aug; 28(7):997-1010. PubMed ID: 18422935
[TBL] [Abstract][Full Text] [Related]
6. Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.
Angulo P; Jorgensen RA; Keach JC; Dickson ER; Smith C; Lindor KD
Hepatology; 2000 Feb; 31(2):318-23. PubMed ID: 10655252
[TBL] [Abstract][Full Text] [Related]
7. Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway.
Tanaka H; Makino Y; Miura T; Hirano F; Okamoto K; Komura K; Sato Y; Makino I
J Immunol; 1996 Feb; 156(4):1601-8. PubMed ID: 8568266
[TBL] [Abstract][Full Text] [Related]
8. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis.
Angulo P; Batts KP; Therneau TM; Jorgensen RA; Dickson ER; Lindor KD
Hepatology; 1999 Mar; 29(3):644-7. PubMed ID: 10051462
[TBL] [Abstract][Full Text] [Related]
9. Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis.
Salas JT; Banales JM; Sarvide S; Recalde S; Ferrer A; Uriarte I; Oude Elferink RP; Prieto J; Medina JF
Gastroenterology; 2008 May; 134(5):1482-93. PubMed ID: 18471521
[TBL] [Abstract][Full Text] [Related]
10. Treatment of primary biliary cirrhosis.
Poupon R; Poupon RE
Baillieres Best Pract Res Clin Gastroenterol; 2000 Aug; 14(4):615-28. PubMed ID: 10976018
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid therapy and the risk of colorectal adenoma in patients with primary biliary cirrhosis: an observational study.
Serfaty L; De Leusse A; Rosmorduc O; Desaint B; Flejou JF; Chazouilleres O; Poupon RE; Poupon R
Hepatology; 2003 Jul; 38(1):203-9. PubMed ID: 12830003
[TBL] [Abstract][Full Text] [Related]
12. Bezafibrate treatment: a new medical approach for PBC patients?
Kanda T; Yokosuka O; Imazeki F; Saisho H
J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
[TBL] [Abstract][Full Text] [Related]
13. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial.
Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Pikkarainen P; Nuutinen H; Färkkilä M
Hepatology; 2005 Apr; 41(4):747-52. PubMed ID: 15754377
[TBL] [Abstract][Full Text] [Related]
14. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis].
Avezov SA; Mansurov FKh
Klin Med (Mosk); 2004; 82(3):55-8. PubMed ID: 15114777
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholic acid enhances glucocorticoid-induced tyrosine aminotransferase-gene expression in cultured rat hepatocytes.
Mitsuyoshi H; Nakashima T; Inaba K; Ishikawa H; Nakajima Y; Sakamoto Y; Matsumoto M; Okanoue T; Kashima K
Biochem Biophys Res Commun; 1997 Nov; 240(3):732-6. PubMed ID: 9398635
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials.
Shi J; Wu C; Lin Y; Chen YX; Zhu L; Xie WF
Am J Gastroenterol; 2006 Jul; 101(7):1529-38. PubMed ID: 16863557
[TBL] [Abstract][Full Text] [Related]
18. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
Olsson R
Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
[TBL] [Abstract][Full Text] [Related]
19. Shared apical sorting of anion exchanger isoforms AE2a, AE2b1, and AE2b2 in primary hepatocytes.
Aranda V; Martínez I; Melero S; Lecanda J; Banales JM; Prieto J; Medina JF
Biochem Biophys Res Commun; 2004 Jul; 319(3):1040-6. PubMed ID: 15184086
[TBL] [Abstract][Full Text] [Related]
20. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy.
Färkkilä M; Rautiainen H; Kärkkäinen P; Karvonen AL; Nurmi H; Niemelä O
Liver Int; 2008 Jul; 28(6):787-97. PubMed ID: 18397236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
